Douglas Manion
Vorstandsvorsitzender bei Flare Therapeutics, Inc.
Vermögen: 49 757 $ am 30.04.2024
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Christopher Boerner | M | 53 | 9 Jahre | |
| Phil Holzer | M | 48 | 11 Jahre | |
| Daphne Karydas | F | 49 |
Flare Therapeutics, Inc.
 Flare Therapeutics, Inc. BiotechnologyHealth Technology Flare Therapeutics is a biotechnology company that focuses on drugging transcription factors to develop small molecule medicines. The company is based in Cambridge, MA. The company's integrated discovery engine converges genetic, biochemical, and chemical insights to reveal druggable pockets and identify small molecule ligands capable of modulating transcription factors of high therapeutic potential. Flare's proteomic and mass spectrometry platform is powered by a proprietary library of electrophilic compounds unique to the company. The team has rapidly established an emerging pipeline of programs, highlighted by FX-909, a first-in-class investigational orally bioavailable small molecule inhibitor of PPARG, a master regulator of the luminal lineage in advanced urothelial cancer that has entered the clinic. Flare Therapeutics was launched in 2021 and is backed by founding investor Third Rock Ventures, as well as Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors, and Eventide Asset Management. The company was founded by Mitchell Lazar, Fraydoon Rastinejad, Robert J. Sims, and Steven L. McKnight. Amit Rakhit has been the CEO of the company since 2022. | 3 Jahre |
| Louis Schmukler | M | - | 13 Jahre | |
| Peter Corr | M | 76 |
Lakewood-Amedex, Inc.
 Lakewood-Amedex, Inc. Pharmaceuticals: MajorHealth Technology Lakewood-Amedex, Inc. engages in the development of treatment for serious infectious diseases. Its product pipeline include Nu-3 cDFU, Nu-3 Oral Mucositis, Nu-8 cUTI, and Nu-8 (Cystic Fibrosis). The company is headquartered in Sarasota, FL. | 4 Jahre |
| Abbie Celniker | M | 65 |
Flare Therapeutics, Inc.
Flare Therapeutics, Inc. BiotechnologyHealth Technology Flare Therapeutics is a biotechnology company that focuses on drugging transcription factors to develop small molecule medicines. The company is based in Cambridge, MA. The company's integrated discovery engine converges genetic, biochemical, and chemical insights to reveal druggable pockets and identify small molecule ligands capable of modulating transcription factors of high therapeutic potential. Flare's proteomic and mass spectrometry platform is powered by a proprietary library of electrophilic compounds unique to the company. The team has rapidly established an emerging pipeline of programs, highlighted by FX-909, a first-in-class investigational orally bioavailable small molecule inhibitor of PPARG, a master regulator of the luminal lineage in advanced urothelial cancer that has entered the clinic. Flare Therapeutics was launched in 2021 and is backed by founding investor Third Rock Ventures, as well as Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors, and Eventide Asset Management. The company was founded by Mitchell Lazar, Fraydoon Rastinejad, Robert J. Sims, and Steven L. McKnight. Amit Rakhit has been the CEO of the company since 2022. | - |
| Lorence Kim | M | 49 |
Flare Therapeutics, Inc.
Flare Therapeutics, Inc. BiotechnologyHealth Technology Flare Therapeutics is a biotechnology company that focuses on drugging transcription factors to develop small molecule medicines. The company is based in Cambridge, MA. The company's integrated discovery engine converges genetic, biochemical, and chemical insights to reveal druggable pockets and identify small molecule ligands capable of modulating transcription factors of high therapeutic potential. Flare's proteomic and mass spectrometry platform is powered by a proprietary library of electrophilic compounds unique to the company. The team has rapidly established an emerging pipeline of programs, highlighted by FX-909, a first-in-class investigational orally bioavailable small molecule inhibitor of PPARG, a master regulator of the luminal lineage in advanced urothelial cancer that has entered the clinic. Flare Therapeutics was launched in 2021 and is backed by founding investor Third Rock Ventures, as well as Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors, and Eventide Asset Management. The company was founded by Mitchell Lazar, Fraydoon Rastinejad, Robert J. Sims, and Steven L. McKnight. Amit Rakhit has been the CEO of the company since 2022. | - |
| Peter Arduini | M | 59 | 8 Jahre | |
| Robert J. Sims | M | - |
Flare Therapeutics, Inc.
Flare Therapeutics, Inc. BiotechnologyHealth Technology Flare Therapeutics is a biotechnology company that focuses on drugging transcription factors to develop small molecule medicines. The company is based in Cambridge, MA. The company's integrated discovery engine converges genetic, biochemical, and chemical insights to reveal druggable pockets and identify small molecule ligands capable of modulating transcription factors of high therapeutic potential. Flare's proteomic and mass spectrometry platform is powered by a proprietary library of electrophilic compounds unique to the company. The team has rapidly established an emerging pipeline of programs, highlighted by FX-909, a first-in-class investigational orally bioavailable small molecule inhibitor of PPARG, a master regulator of the luminal lineage in advanced urothelial cancer that has entered the clinic. Flare Therapeutics was launched in 2021 and is backed by founding investor Third Rock Ventures, as well as Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors, and Eventide Asset Management. The company was founded by Mitchell Lazar, Fraydoon Rastinejad, Robert J. Sims, and Steven L. McKnight. Amit Rakhit has been the CEO of the company since 2022. | - |
| Charles Frederick Wright | M | - |
Lakewood-Amedex, Inc.
Lakewood-Amedex, Inc. Pharmaceuticals: MajorHealth Technology Lakewood-Amedex, Inc. engages in the development of treatment for serious infectious diseases. Its product pipeline include Nu-3 cDFU, Nu-3 Oral Mucositis, Nu-8 cUTI, and Nu-8 (Cystic Fibrosis). The company is headquartered in Sarasota, FL. | - |
| Arnav Mehta | M | - |
Flare Therapeutics, Inc.
Flare Therapeutics, Inc. BiotechnologyHealth Technology Flare Therapeutics is a biotechnology company that focuses on drugging transcription factors to develop small molecule medicines. The company is based in Cambridge, MA. The company's integrated discovery engine converges genetic, biochemical, and chemical insights to reveal druggable pockets and identify small molecule ligands capable of modulating transcription factors of high therapeutic potential. Flare's proteomic and mass spectrometry platform is powered by a proprietary library of electrophilic compounds unique to the company. The team has rapidly established an emerging pipeline of programs, highlighted by FX-909, a first-in-class investigational orally bioavailable small molecule inhibitor of PPARG, a master regulator of the luminal lineage in advanced urothelial cancer that has entered the clinic. Flare Therapeutics was launched in 2021 and is backed by founding investor Third Rock Ventures, as well as Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors, and Eventide Asset Management. The company was founded by Mitchell Lazar, Fraydoon Rastinejad, Robert J. Sims, and Steven L. McKnight. Amit Rakhit has been the CEO of the company since 2022. | 3 Jahre |
| Lamine Mbow | M | - | 3 Jahre | |
| Zack Newman | M | - | 11 Jahre | |
| William Perhacs | M | - | 17 Jahre | |
| Harvey Schonwald | M | - |
Lakewood-Amedex, Inc.
Lakewood-Amedex, Inc. Pharmaceuticals: MajorHealth Technology Lakewood-Amedex, Inc. engages in the development of treatment for serious infectious diseases. Its product pipeline include Nu-3 cDFU, Nu-3 Oral Mucositis, Nu-8 cUTI, and Nu-8 (Cystic Fibrosis). The company is headquartered in Sarasota, FL. | - |
| Ali Baker | F | - |
Flare Therapeutics, Inc.
Flare Therapeutics, Inc. BiotechnologyHealth Technology Flare Therapeutics is a biotechnology company that focuses on drugging transcription factors to develop small molecule medicines. The company is based in Cambridge, MA. The company's integrated discovery engine converges genetic, biochemical, and chemical insights to reveal druggable pockets and identify small molecule ligands capable of modulating transcription factors of high therapeutic potential. Flare's proteomic and mass spectrometry platform is powered by a proprietary library of electrophilic compounds unique to the company. The team has rapidly established an emerging pipeline of programs, highlighted by FX-909, a first-in-class investigational orally bioavailable small molecule inhibitor of PPARG, a master regulator of the luminal lineage in advanced urothelial cancer that has entered the clinic. Flare Therapeutics was launched in 2021 and is backed by founding investor Third Rock Ventures, as well as Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors, and Eventide Asset Management. The company was founded by Mitchell Lazar, Fraydoon Rastinejad, Robert J. Sims, and Steven L. McKnight. Amit Rakhit has been the CEO of the company since 2022. | 2 Jahre |
| Steven Paul | M | 73 |
Flare Therapeutics, Inc.
Flare Therapeutics, Inc. BiotechnologyHealth Technology Flare Therapeutics is a biotechnology company that focuses on drugging transcription factors to develop small molecule medicines. The company is based in Cambridge, MA. The company's integrated discovery engine converges genetic, biochemical, and chemical insights to reveal druggable pockets and identify small molecule ligands capable of modulating transcription factors of high therapeutic potential. Flare's proteomic and mass spectrometry platform is powered by a proprietary library of electrophilic compounds unique to the company. The team has rapidly established an emerging pipeline of programs, highlighted by FX-909, a first-in-class investigational orally bioavailable small molecule inhibitor of PPARG, a master regulator of the luminal lineage in advanced urothelial cancer that has entered the clinic. Flare Therapeutics was launched in 2021 and is backed by founding investor Third Rock Ventures, as well as Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors, and Eventide Asset Management. The company was founded by Mitchell Lazar, Fraydoon Rastinejad, Robert J. Sims, and Steven L. McKnight. Amit Rakhit has been the CEO of the company since 2022. | - |
| Tim Power | M | - | 18 Jahre | |
| Aaron Davis | M | 45 |
Flare Therapeutics, Inc.
Flare Therapeutics, Inc. BiotechnologyHealth Technology Flare Therapeutics is a biotechnology company that focuses on drugging transcription factors to develop small molecule medicines. The company is based in Cambridge, MA. The company's integrated discovery engine converges genetic, biochemical, and chemical insights to reveal druggable pockets and identify small molecule ligands capable of modulating transcription factors of high therapeutic potential. Flare's proteomic and mass spectrometry platform is powered by a proprietary library of electrophilic compounds unique to the company. The team has rapidly established an emerging pipeline of programs, highlighted by FX-909, a first-in-class investigational orally bioavailable small molecule inhibitor of PPARG, a master regulator of the luminal lineage in advanced urothelial cancer that has entered the clinic. Flare Therapeutics was launched in 2021 and is backed by founding investor Third Rock Ventures, as well as Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors, and Eventide Asset Management. The company was founded by Mitchell Lazar, Fraydoon Rastinejad, Robert J. Sims, and Steven L. McKnight. Amit Rakhit has been the CEO of the company since 2022. | - |
| Thomas Pfisterer | M | 42 |
Lakewood-Amedex, Inc.
Lakewood-Amedex, Inc. Pharmaceuticals: MajorHealth Technology Lakewood-Amedex, Inc. engages in the development of treatment for serious infectious diseases. Its product pipeline include Nu-3 cDFU, Nu-3 Oral Mucositis, Nu-8 cUTI, and Nu-8 (Cystic Fibrosis). The company is headquartered in Sarasota, FL. | 2 Jahre |
| Michael Meyers | M | 74 |
Flare Therapeutics, Inc.
Flare Therapeutics, Inc. BiotechnologyHealth Technology Flare Therapeutics is a biotechnology company that focuses on drugging transcription factors to develop small molecule medicines. The company is based in Cambridge, MA. The company's integrated discovery engine converges genetic, biochemical, and chemical insights to reveal druggable pockets and identify small molecule ligands capable of modulating transcription factors of high therapeutic potential. Flare's proteomic and mass spectrometry platform is powered by a proprietary library of electrophilic compounds unique to the company. The team has rapidly established an emerging pipeline of programs, highlighted by FX-909, a first-in-class investigational orally bioavailable small molecule inhibitor of PPARG, a master regulator of the luminal lineage in advanced urothelial cancer that has entered the clinic. Flare Therapeutics was launched in 2021 and is backed by founding investor Third Rock Ventures, as well as Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors, and Eventide Asset Management. The company was founded by Mitchell Lazar, Fraydoon Rastinejad, Robert J. Sims, and Steven L. McKnight. Amit Rakhit has been the CEO of the company since 2022. | 1 Jahre |
| Leonard J. DeRoma | M | - |
Lakewood-Amedex, Inc.
Lakewood-Amedex, Inc. Pharmaceuticals: MajorHealth Technology Lakewood-Amedex, Inc. engages in the development of treatment for serious infectious diseases. Its product pipeline include Nu-3 cDFU, Nu-3 Oral Mucositis, Nu-8 cUTI, and Nu-8 (Cystic Fibrosis). The company is headquartered in Sarasota, FL. | 7 Jahre |
| Jigar Raythatha | M | 47 |
Flare Therapeutics, Inc.
Flare Therapeutics, Inc. BiotechnologyHealth Technology Flare Therapeutics is a biotechnology company that focuses on drugging transcription factors to develop small molecule medicines. The company is based in Cambridge, MA. The company's integrated discovery engine converges genetic, biochemical, and chemical insights to reveal druggable pockets and identify small molecule ligands capable of modulating transcription factors of high therapeutic potential. Flare's proteomic and mass spectrometry platform is powered by a proprietary library of electrophilic compounds unique to the company. The team has rapidly established an emerging pipeline of programs, highlighted by FX-909, a first-in-class investigational orally bioavailable small molecule inhibitor of PPARG, a master regulator of the luminal lineage in advanced urothelial cancer that has entered the clinic. Flare Therapeutics was launched in 2021 and is backed by founding investor Third Rock Ventures, as well as Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors, and Eventide Asset Management. The company was founded by Mitchell Lazar, Fraydoon Rastinejad, Robert J. Sims, and Steven L. McKnight. Amit Rakhit has been the CEO of the company since 2022. | 1 Jahre |
| Geoffrey F. Cox | M | 80 |
Lakewood-Amedex, Inc.
Lakewood-Amedex, Inc. Pharmaceuticals: MajorHealth Technology Lakewood-Amedex, Inc. engages in the development of treatment for serious infectious diseases. Its product pipeline include Nu-3 cDFU, Nu-3 Oral Mucositis, Nu-8 cUTI, and Nu-8 (Cystic Fibrosis). The company is headquartered in Sarasota, FL. | 11 Jahre |
| Jakob Loven | M | 46 |
Flare Therapeutics, Inc.
Flare Therapeutics, Inc. BiotechnologyHealth Technology Flare Therapeutics is a biotechnology company that focuses on drugging transcription factors to develop small molecule medicines. The company is based in Cambridge, MA. The company's integrated discovery engine converges genetic, biochemical, and chemical insights to reveal druggable pockets and identify small molecule ligands capable of modulating transcription factors of high therapeutic potential. Flare's proteomic and mass spectrometry platform is powered by a proprietary library of electrophilic compounds unique to the company. The team has rapidly established an emerging pipeline of programs, highlighted by FX-909, a first-in-class investigational orally bioavailable small molecule inhibitor of PPARG, a master regulator of the luminal lineage in advanced urothelial cancer that has entered the clinic. Flare Therapeutics was launched in 2021 and is backed by founding investor Third Rock Ventures, as well as Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors, and Eventide Asset Management. The company was founded by Mitchell Lazar, Fraydoon Rastinejad, Robert J. Sims, and Steven L. McKnight. Amit Rakhit has been the CEO of the company since 2022. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Frank Ruffo | M | 58 | 10 Jahre | |
| Thomas Lynch | M | 63 |
Kleo Pharmaceuticals, Inc.
 Kleo Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Kleo Pharmaceuticals, Inc. is a biotechnology company, which engages in the development of biospecific compounds designed to emulate and enhance the activity of biologics. Its compounds are designed to direct the immune system to destroy cancerous or virally infected cells, and treatment of multiple myeloma and COVID-19. It offers Antibody Recruiting Molecules (ARMs),Synthetic Antibody Mimics (SyAMs), and Monoclonal Antibody Therapy Enhancers (MATEs) pipeline. The company was founded by David A. Spiegel and Roy Prieb in 2015 and is headquartered in New Haven, CT. | 6 Jahre |
| Peter R. Dolan | M | 68 | 18 Jahre | |
| James Cornelius | M | 81 | 10 Jahre | |
| John E. Celentano | M | 64 | 31 Jahre | |
| Vicki Sato | M | 75 | 15 Jahre | |
| Alan J. Lacy | M | 70 | 12 Jahre | |
| Louis Gerstner | M | - | - | |
| Leif Valdemar Johansson | M | 73 | 13 Jahre | |
| Carl Decicco | M | 62 | 10 Jahre | |
| Jason Haddock | M | 54 | 14 Jahre | |
| Gerald Storch | M | 67 | 12 Jahre | |
| Gerald Bruce | M | 68 | 8 Jahre | |
| Brian Daniels | M | 65 | 14 Jahre | |
| David J. Helfgott | M | - | - | |
| Charles Sigal | M | 72 | 16 Jahre | |
| Michael Grobstein | M | 81 | 13 Jahre | |
| Togo Dennis West | M | 81 | 10 Jahre | |
| James Robinson | M | 88 | 29 Jahre | |
| Béatrice J. Cazala | F | 67 | 32 Jahre | |
| Anthony Hooper | M | 69 | 15 Jahre | |
| Louis J. Freeh | M | 74 | 8 Jahre | |
| Robert Williams | M | 75 | 7 Jahre | |
| Dinesh C. Paliwal | M | 67 | 8 Jahre | |
| John Tsai | M | 57 | 11 Jahre | |
| Lewis B. Campbell | M | 77 | 18 Jahre | |
| Qin Xia | F | 56 | 1 Jahre | |
| Rebecca Drain | F | 61 | 3 Jahre | |
| Linda Jordan | F | - | - | |
| James Patrick McDermott | M | - | 3 Jahre | |
| John Golubieski | M | 59 | 16 Jahre | |
| Kyu-Sung Lee | M | 64 | 5 Jahre | |
| Ann Powell | F | 58 | 10 Jahre | |
| Thomas J. McKearn | M | 75 | 10 Jahre | |
| Julie Hambleton | M | 66 | 1 Jahre | |
| Ranya Dajani | F | - | - | |
| Robert G. Petit | M | 64 | 5 Jahre | |
| David Berman | M | - | 10 Jahre | |
| Fred Grossman | M | 62 | 6 Jahre | |
| Karen Murphy Santiago | F | 53 | 10 Jahre | |
| Charles Albright | M | 66 | 12 Jahre | |
| Lynn Sadowski Mason | F | 45 | 2 Jahre | |
| Randall Owen | M | - | 6 Jahre | |
| James Daniel Guylain Priour | M | 57 | - | |
| Tamar Thompson | F | 50 | 4 Jahre | |
| Kevin McManus | M | - | 9 Jahre | |
| Luis Maranga | M | - | - | |
| Mohamed Ragab | M | - | - | |
| Frances K. Heller | F | 57 | - | |
| Michael Burgess | M | 61 | - | |
| Ellen Futter | F | 74 | 6 Jahre | |
| Stephen E. Bear | M | 73 | 7 Jahre | |
| John L. McGoldrick | M | 83 | 10 Jahre | |
| Kimberly A. Hendricks | F | 60 | 3 Jahre | |
| Andrew Shenker | M | 69 | 5 Jahre | |
| Freda Lewis-Hall | M | 69 | 5 Jahre | |
| Lynn H. Clark | F | 66 | 8 Jahre | |
| Mark Prudenti | M | - | 2 Jahre | |
| Kenneth Bahrt | M | 71 | 3 Jahre | |
| Holly Tyson | F | 52 | 8 Jahre | |
| Stuart Tross | M | 57 | 8 Jahre | |
| Louis Sullivan | M | 90 | - | |
| Claude Nicaise | M | 71 | 25 Jahre | |
| Richard K. Willard | M | 75 | 2 Jahre | |
| Tamar Howson | F | 75 | 6 Jahre | |
| John P. Amos | M | 57 | 2 Jahre | |
| David Ian Johnson | M | 66 | 12 Jahre | |
| Matthew Ros | M | 57 | 17 Jahre | |
| Katrin Rupalla | M | 56 | 7 Jahre | |
| Kelly Schick | F | 44 | - | |
| Mark Trudeau | M | 62 | 11 Jahre | |
| Raymond T. Keane | M | 65 | 20 Jahre | |
| Laurie Alsup | M | 70 | 10 Jahre | |
| Howard Feldman | M | - | - | |
| Danielle Halstrom | F | - | 7 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 100 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Douglas Manion
- Persönliches Netzwerk
